Prosecution Insights
Last updated: November 08, 2026
Application No. 18/895,123

METHODS FOR TREATING IMMUNODEFICIENCY DISEASE

Non-Final OA §DP
Filed
Sep 24, 2024
Priority
Dec 22, 2015 — provisional 62/271,087 +5 more
Examiner
RAO, SAVITHA M
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
X4 Pharmaceuticals Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
6m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
727 granted / 1197 resolved
+0.7% vs TC avg
Strong +30% interview lift
Without
With
+29.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
42 currently pending
Career history
1229
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1197 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim 21-40 are pending and are under consideration in the instant office action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 05/02/2022 and 01/19/2024 complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits. See attached copy of the PTO-1449. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over each of the following over claim 1-16 of U. S. Patent No 10,610.527 (‘527) An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Instant claims 21-24 are drawn to a method of treating WHIM syndrome in a patient in need thereof by administering: i) an effective amount of X4P-001 or a pharmaceutically acceptable salt or a composition thereof; and ii) an effective amount of an agent selected from the group consisting of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and intravenous immunoglobulin (IVIG). Claims 25-30 are drawn to a method of treating myelokathexis associated with a mutation in CXCR4 in a patient in need thereof by administering an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof. Instant claims 33-40 are drawn to a method of treating WHIM syndrome or myelokathexis in a patient in need thereof by administering an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof. Claims 1-20 of ‘527 are drawn to a method for treating WHIM syndrome in a patient in need thereof, wherein said method comprises administering to said patient an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof. Although the conflicting claims are not identical, they are not patentably distinct from each other. Claims of instant application and co-pending ‘527 claims are both drawn to a method of treating the same disease, WHIM syndrome in a patient in need thereof, administering to said patient an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claims 21-24 are claiming essentially the same as what is claimed in ‘527 and as such is obvious to a person of ordinary skill in the art. Myelokathexis forms the M in the WHIM disease and is part of the immunodeficiency disease WHIM which includes tetrad of warts, hypogammaglobulinemia, Infections and Myelokathexis. Treatment of WHIM’s syndrome by inhibiting CDCR4 receptor would inherently also treat Myelokathexis which is one of the features of the WHIM syndrome and as such the subject matter disclosed in claims instant claims 21-40 of the instant application is fully taught in claims 1-16 of patent ‘479 and hence renders obvious and anticipates the instant claims. Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over each of the following over claim 1-19 of U.S. Patent No. 11,217,621 (‘621) in view of Dale et al (US 2015/0030561). Instant claims 21-24 are drawn to a method of treating WHIM syndrome in a patient in need thereof by administering: i) an effective amount of X4P-001 or a pharmaceutically acceptable salt or a composition thereof; and ii) an effective amount of an agent selected from the group consisting of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and intravenous immunoglobulin (IVIG). Instant claims 33-40 are drawn to a method of treating WHIM syndrome or myelokathexis in a patient in need thereof by administering an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof. Claims 1-19 of ‘621 are drawn to a method for treating WHIM syndrome in a patient in need thereof, comprising administering to the patient about 200 mg, about 250 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, or about 600 mg of X4P-00 I or a pharmaceutically acceptable salt or composition thereof per day in a single or divided dose. Myelokathexis forms the M in the WHIM disease and is part of the immunodeficiency disease WHIM which includes tetrad of warts, hypogammaglobulinemia, Infections and Myelokathexis. Treatment of WHIM’s syndrome by inhibiting CDCR4 receptor would inherently also treat Myelokathexis which is one of the features of the WHIM syndrome It is noted that the claims in the patents does not specifically recite an effective amount of an agent selected from the group consisting of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and intravenous immunoglobulin (IVIG). However, Dale et al. disclose methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist and they teach that their inventive CXCR4 antagonist is administered in combination with an anti-infective or anti-inflammatory agent. For example, the compounds of formula I may be administered in combination with gammaglobulin, immunoglobulin, cytokines, e.g., G-CSF, GM-CSF, IL-3, stem cell factor, fit-3 ligand, macrophage inflammatory protein. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. The idea of combining them flows logically from their having been individually taught in the prior art”. In re Kerkhoven, 626 F .2d 846, 850 205 USPQ 1069, 1072 (CCPA 1980). As such it would have been obvious to a person of ordinary skill in the art to combine the WHIM treating X4P-00 taught by the parent patents with agents such as immunoglobulin, G-SCF, GM-CSF taught by Dale et al. also for treating WHIM syndrome thus rendering them obvious over the instantly claimed claims. . Conclusion Claims 21- 40 are rejected. No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAVITHA RAO whose telephone number is (571)270-5315. The examiner can normally be reached on Mon-Fri 7.00 am to 4.00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner' s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAVITHA M RAO/ Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Sep 24, 2024
Application Filed
Sep 11, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778930
PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST
3y 5m to grant Granted Nov 03, 2026
Patent 12778905
CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD
3y 1m to grant Granted Nov 03, 2026
Patent 12758515
METHOD OF TREATING DIABETES AND RELATED METABOLIC DISEASE BY ACAT INHIBITION
5y 4m to grant Granted Oct 13, 2026
Patent 12758567
COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
3y 2m to grant Granted Oct 13, 2026
Patent 12758524
PROPHYLACTIC OR THERAPEUTIC DRUG FOR PARKINSON'S DISEASE
2y 9m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
90%
With Interview (+29.7%)
2y 8m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1197 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month